Immune cell shot aims to tame tough lupus cases
NCT ID NCT06676631
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding NK cells (a type of immune cell) to the standard drug rituximab can safely help people with severe lupus or lupus-related kidney disease. The study will enroll 18 adults in China and focus on safety and signs of disease improvement. It is too early to know if this combination will be effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NK cells (NK010 or NK042) plus rituximab
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-control lupus or lupus kidney disease.
- What could go wrong
- This is a very early, small phase 1 trial with only 18 people. It primarily tests safety, not whether it works. Side effects from the NK cells or rituximab are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdomg, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lupus patients get hope from Cancer-Fighting cell therapy
- Lupus patients may get new hope from In-Body cell therapy
- Immune cell therapy shows promise for Tough-to-Treat lupus
- Engineered immune cells take on lupus, scleroderma, and Sjogren's
- Could CAR T-Cells tame tough lupus? tiny trial aims to find out
- CAR T-Cell therapy: what happens years later?